Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

ASCO MEETING: MGI 114 Shows Antitumour Activity In Prostate Cancer Patients MINNEAPOLIS, MN -- May 17, 1999 -- MGI Pharma, Inc.’s MGI 114 has shown significant antitumour activity in patients with hormone-refractory prostate cancer, according to a study presented today at the annual meeting of the American Society for Clinical Oncology (ASCO) in Atlanta. Patients involved in the study have prostate tumours that have stopped responding to hormone-based therapies. "Prostate cancer is the most frequently diagnosed malignancy in American men," said Dr. Neil Senzer, a lead investigator of the MGI 114 prostate study at Sammons Cancer Center, Dallas. "We are encouraged by the anti-tumour activity we have seen with MGI 114 against hormone-resistant prostate tumours. As a result of early positive responses, we expanded the trial late last year. Patient enrolment is now nearly complete." The phase II clinical study in patients with hormone-refractory prostate cancer was designed to assess the anti-tumour activity of MGI 114 as a single agent, measured by a decrease in serum prostate specific antigen (PSA) in up to 30 patients. To date, 76 percent of the patients evaluable for PSA response (16/21) have shown stable or decreasing PSA levels. The drug is well tolerated in this patient population and nine patients have received four or more courses of treatment. In 1998, there were approximately 184,500 new cases of prostate cancer diagnosed in the United States and more than 39,000 men died from it. More than $2 billion US is spent annually on prostate cancer treatment in the U.S. Derived from a mushroom, MGI 114 is the lead member of a family of novel chemotherapy agents called acylfulvenes that appear to have several potential advantages over existing cancer therapies. Tumour cells die as a result of MGI 114 binding to DNA and/or protein targets within the cell that initiate apoptosis (programmed cell death), leading to tumour shrinkage or elimination. In previous preclinical studies, MGI 114 has demonstrated activity against a wide variety of tumour types, including drug-resistant tumours such as ovarian and pancreatic cancers. E-mail this page to a friend or colleague! To print, use this version